Fresh off two new FDA nods, Merck's high-flying Keytruda nets priority status in stomach cancer

23rd May 2017 Uncategorised 0

It’s good to be Merck these days. Less than a week after its immuno-oncology med Keytruda nabbed an FDA go-ahead in bladder cancer, the company scored a speedy review for the therapy in stomach cancer.

More: Fresh off two new FDA nods, Merck's high-flying Keytruda nets priority status in stomach cancer
Source: fierce